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Abstract
Background: This study aimed to investigate the molecular structural relationship between cell adhesive molecule
CD44 and Lewis y antigen, and determine the effects of Lewis y antigen on CD44-mediated adhesion and
spreading of ovarian cancer cell line RMG-I and the Lewis y antigen-overexpressed cell line RMG-I-H.
Methods: The expression of CD44 in RMG-I and RMG-I-H cells before and after treatment of Lewis y monoclonal
antibody was detected by immunocytochemistry; the expression of Lewis y antigen and CD44 was detected by
Western Blot. The structural relationship between Lewis y antigen and CD44 was determined by
immunoprecipitation and confocal laser scanning microscopy. The adhesion and spreading of RMG-I and RMG-I-H
cells on hyaluronic acid (HA) were observed. The expression of CD44 mRNA in RMG-I and RMG-I-H cells was
detected by real-time RT-PCR.
Results: Immunocytochemistry revealed that the expression of CD44 was significantly higher in RMG-I-H cells than
in RMG-I cells (P < 0.01), and its expression in both cell lines was significantly decreased after treatment of Lewis y
monoclonal antibody (both P < 0.01). Western Blot confirmed that the content of CD44 in RMG-I-H cells was 1.46
times of that in RMG-I cells. The co-location of Lewis y antigen and CD44 was confirmed by co-
immunoprecipitation. The co-expression of CD44 and Lewis y antigen in RMG-I-H cells was 2.24 times of that in
RMG-I cells. The adhesion and spreading of RMG-I-H cells on HA were significantly enhanced as compared to those
of RMG-I cells (P < 0.01), and this enhancement was inhibited by Lewis y monoclonal antibody (P < 0.01). The
mRNA level of CD44 in both cell lines was similar (P > 0.05).
Conclusion: Lewis y antigen strengthens CD44-mediated adhesion and spreading of ovarian cancer cells.
Background
Glycosylated antigens, important components of glycoli-
pids and glycoproteins, are widely expressed on cell
membrane and are involved in cell adhesion, recogni-
tion, and signal transduction [1]. The alterations of type
II sugar chains, such as Lewis × and Lewis y, are com-
mon in ovarian cancer: 75% of epithelial ovarian cancers
have overexpression of Lewis y antigen which shows
obvious relationship with prognosis; tumor marker
CA125 in epithelial ovarian cancer also contains Lewis y
structure [2,3]. Alpha1, 2-fucosyltransferase (a1, 2-FT)
is a key enzyme for synthesizing Lewis y antigen. In our
previous study, we successfully transferred a1, 2-FT
gene into ovarian cancer cell line RMG-I and established
a cell line RMG-I-H with stable high expression of
Lewis y antigen, which showed obviously enhanced
malignant behaviors [4-6].
CD44, one of important adhesive molecules on cells, is
involved in the adhesion and metastasis of tumor cells
and plays an important role in tumor development
[7-10], but the regulatory mechanism is unclear yet. The
molecule CD44 is abundant of a-L-fucose, and is an
important a1, 2-fucose antigen-containing protein on
the surface of cells [11]. CD44 is expressed on several
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tissue cells, binds to receptors in extracellular matrix
such as hyaluronic acid (HA) and laminin, and mediates
cell-cell and cell-matrix adhesion [12,13]. The present
study aimed to determine the impact of a1, 2-FT gene
transfection on the expression of CD44 on cells and the




Lewis y monoclonal antibody was purchased from
Abcam Co.; CD44 monoclonal antibody from Santa
Cruz Co. and Wuhan Boster Co.; Protein A-agarose,
ECL chromogenic agent, and 5× SDS-PAGE loading
buffer from Shanghai Beyotime Institute of Biotechnol-
ogy; SABC kit from Beijing Zhongshan Golden Bridge
Biotechnology Co., Ltd; HA from Hefei Bomei Biotech-
nology Co., Ltd; DMEM culture medium from Gibco
Co.; fetal bovine serum (FBS) from Shenyang Boermei
Reagent Co.; Coomassie brilliant blue from Beijing
Solarbio Science & Technology Co., Ltd; Trizol reagent,
PrimeScript™RT reagent kit, and SYBR® Premix Ex
Taq™from Dalian TaKaRa Biotechnology Co. The
sequences of primers were synthesized by Shanghai Invi-
trogen Co.
Cell line and cell culture
The cell line RMG-I was originated from ovarian clear
cell cancer tissues. The cell line RMG-I-H with high
expression of a1, 2-FT and Lewis y antigen was estab-
lished in our lab [14]. RMG-I and RMG-I-H cells
were cultured in DMEM medium containing 10% FBS
at 37°C in 5% CO2 and saturated humidity. Cells are
grouped in immunocytochemistry, cell spreading, cell
adhesion as follows: negative groups, Lewis y antibody-
untreated groups, Lewis y antibody-treated groups
(single layer cells were treated with 10 μg/mL Lewis y
monoclonal antibody at 37°C in 5% CO2 for 60 min),
irrelevant isotype-matched control(10 μg/mL normal
mouse IgM).
Immunocytochemistry
RMG-I-H and RMG-I cells at exponential phase of
growth were digested by 0.25% trypsin and cultured in
DMEM medium containing 10% FBS to prepare single-
cell suspension. Cells were washed twice with cold PBS
when growing in a single layer, and fixed with 4% paraf-
ormaldehyde for 30 min. The expression of CD44 on
cells was detected according to the SABC kit instruc-
tions. The concentration of CD44 monoclonal antibody
was 1:100. The primary antibody was replaced by PBS
for negative control. 10 μg/mL normal mice IgM acted
as irrelevant isotype-matched control. The average opti-
cal densities were measured under a microscope with
image processing, being presented as the means ± stan-
dard deviation for three separate experiments.
Confocal laser scanning microscopy
After fixing with 4% paraformaldehyde, RMG-I-H cells
were treated by the one-step immunofluorescence dual-
labeling method. In brief, mouse anti-human Lewis y
antibody and rabbit anti-human CD44 antibody were
diluted to 1:100 as primary antibody solutions; goat
anti-rabbit TRITC-labeled secondary antibody and goat
anti-mouse FITC-labeled secondary antibody were
diluted to 1:200. Cells were blocked by normal goat
serum for 30 min, added with primary antibody solu-
tions at 37°C for 1 h, then cultured at room temperature
overnight. After washing with PBS, cells were added
with secondary antibody solutions at 37°C for 1 h,
stained with 4, 6-diamidino-2-phenylindole (PI) for
5 min, then observed under the confocal laser scanning
microscope. The data were colleted by a computer for
digital imaging. The experiment was repeated 3 times.
Western Blot
RMG-I-H and RMG-I cells at exponential phase of
growth were washed twice with cold PBS, added with
cell lysis buffer (0.2 mL/bottle), placed on ice for
15 min, then centrifuged at 14,000 rpm for 15 min. The
protein concentration in the supernatant was detected
by the method of Coomassie brilliant blue. The superna-
tant was cultured with 1× SDS-PAGE loading buffer at
100°C for 5 min for protein denaturation. Then, 50 μg
of the protein was used for SDS-PAGE gel electrophor-
esis. The protein was transferred onto PVDF membrane,
blocked by 5% fat-free milk powder at room tempera-
ture for 2 h, added with primary mouse anti-human
CD44 monoclonal antibody (1:200) and mouse anti-
human Lewis y monoclonal antibody (1:1000) and
cultured at 4°C overnight, then added with secondary
HRP-labeled goat anti-mouse IgG (1:5000) and cultured
at room temperature for 2 h, and finally visualized by
ECL reagent. The experiment was repeated 3 times.
Co-immunoprecipitation
The protein was extracted from cells before and after
transfection with the method described in Western Blot
section. After protein quantification, 500 μg of each cell
lysis was added with 1 μg of CD44 monoclonal antibody
and shaken at 4°C overnight, then added with 40 μL of
Protein A-agarose and shaken at 4°C for 2 h, finally cen-
trifuged at 2500 rpm for 5 min and washed to collect
the precipitation. The precipitated protein was added
with 20 μL of 1× SDS-PAGE loading buffer at 100°C for
5 min for denaturation. The supernatant was subjected
to SDS-PAGE gel electrophoresis. Lewis y monoclonal
antibody (1:1000) was used to detect Lewis y antigen.
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Other steps were the same as described in Western Blot
section.
Cell spreading
The 2 mg/mL HA-coated 35-mm culture dishes were
placed at 37°C for 1 h, and then blocked by 1% bovine
serum albumin (BSA) for 1 h. The single-cell suspension
(15,000/mL) prepared with serum-free DMEM was
added to the dishes (1 mL/well) and cultured at 37°C in
5% CO2 for 90 min. Under the inverted microscope, 3
to 5 visual fields (×200) were randomly selected to
count 200 cells: the round and bright cells were counted
as non-spreading cells; the oval cells with pseudopods
were counted as spreading cells. Irrelevant control anti-
bodies (10 mg/ml) are used to evaluate the specificity of
the inhibitions. The experiment was repeated 3 times.
Cell adhesion
The 96-well plates were coated with 2 mg/ml HA (50
μL/well). The plate coated with 3 mg/mL polylysine
and 1% BSA was used as maximal and minimal adhe-
sion controls, respectively. After 2-hour coating at
37°C, the plates were washed twice with PBS, and
blocked again with 1% BSA for 2 h. The cells were
digested by 0.25% trypsin, centrifuged at 1000 rpm for
5 min, and then added with serum-free DMEM cul-
ture medium to prepare single-cell suspension. Cells
were diluted to 5 × 104/mL, added to coated plates
(100 μL/well) and cultured at 37°C in 5% CO2 for 2 h.
After washing off the un-adhered cells, the 96-well
plates were fixed by 4% paraformaldehyde for 30 min,
stained with 0.5% crystal violet (100 μL/well) for 2 h,
and then washed twice with cold PBS. The absorbance
at 597 nm (A597 absorbance represents the adhesive
cells) was detected by a microplate reader. Irrelevant
control antibodies (10 mg/ml) are used to evaluate the
specificity of the inhibitions. The experiment was
repeated 3 times.
Detecting CD44 mRNA in RMG-I and RMG-I-H cells by
real-time PCR
RMG-I and RMG-I-H cells at exponential phase of
growth were added with Trizol reagent (1 mL per 1 × 107
cells) to extract total RNA. The concentration and purity
of RNA were detected by an ultraviolet spectrometer.
cDNA was synthesized according to the RNA reverse
transcription kit instructions (TaKaRa Co.). The reaction
system contained 4 µL of 5× PrimeScript™Buffer, 1 µL
of PrimeScript™RT Enzyme Mix I, 1 µL of 50 µmol/L
Oligo dT Primer, 1 µL of 100 µmol/L Random 6 mers,
2 µL of total RNA, and 11 µL of RNase-free dH2O. The
reaction conditions were 37°C for 15 min, 85°C for 5 s,
and 4°C for 5 min. The sequences of CD44 gene primers
were 5’-CCAATGCCTTTGATGGACCA-3’ for forward
primer and 5’-TGTGAGTGTCCATCTGATTC-3’ for
reverse primer. The sequences of a1,2-FT gene primers
were 5’-AGGTCATCCCTGAGCTGAAACGG-3’ for for-
ward primer and 5’-CGCCTGCTTCACCACCTTCTTG-
3’ for reverse primer. The sequences of b-actin gene
primers were 5’-GGACTTCGAGCAAGAGATGG-3’ for
forward primer and 5’-ACATCTGCTGGAAGGTG-
GAC-3’ for reverse primer. The reaction system for
real-time fluorescent PCR contained 5 µL of 2× SYBR®
Premix Ex Taq™, 0.5 μL of 5 μmol/L PCR forward
primer, 0.5 μL of 5 μmol/L PCR reverse primer, 1 µL
of cDNA, and 3 µL of dH2O. The reaction conditions
were 45 cycles of denaturation at 95°C for 20 s and
annealing at 60°C for 60 s. The Light Cycler PCR sys-
tem (Roche Diagnostics, Mannheim, Germany) was
used for real-time PCR amplification and Ct value
detection. The melting curves were analyzed after
amplification. PCR reactions of each sample were done
in triplicate. Data were analyzed through the compara-
tive threshold cycle (CT) method.
Statistical analyses
All data are expressed as mean ± standard deviation and
were processed by the SPSS17.0 software. Raw data
were analyzed by the variance analysis. A value of P <
0.05 was considered to be statistically significant.
Results
The expression of CD44 in RMG-I and RMG-I-H cells
Immunocytochemistry showed that the positive CD44
staining presented as light yellow particles in the cyto-
plasm of RMG-I cells and brown-yellow particles in the
cytoplasm and on the membrane of RMG-I-H cells
(Figure 1). The relative level of CD44 expression was
significantly higher in RMG-I-H cells than in RMG-I
cells (P < 0.01) (Table 1).
After treatment of Lewis y monoclonal antibody, the
expression of CD44 was decreased in both RMG-I-H
cells and RMG-I cells (P < 0.01), moreover showed no
significant difference between the two cell lines (P >
0.05); after treatment of normal mouse IgM, the expres-
sion of CD44 did not change in RMG-I-H cells and
RMG-I cells, compared with Lewis y antibody-untreated
groups(Figure 1 Table 1).
Co-location of CD44 and Lewis y antigen on RMG-I-H cells
Under the confocal laser scanning microscope, CD44
presented red fluoscence mainly on cell membrane and
partly in cytoplasm; Lewis y antigen presented green
fluoscence mainly on cell membrane (Figure 2). Both
red fluoscence and green fluoscence were accumulated
at the margin of cell clusters and overlapped as yellow
fluoscence, indicating the co-location of CD44 and
Lewis y antigen.
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The expression of CD44 and Lewis y antigen in RMG-I
and RMG-I-H cells
Western Blot showed that the expression of CD44 in
RMG-I-H cells was significantly increased by 1.46 times
of that in RMG-I cells (P < 0.01) (Figure 3.BD), and the
expression of Lewis y antigen was significantly increased
by 2.98 times (P < 0.01) (Figure 3.AD). Immunoprecipi-
tation showed that, using the ratio of Lewis y antigen
expression to CD44 expression to represent the relative
expression of Lewis y antigen in CD44, the expression
of Lewis y antigen in RMG-I-H cells was increased by
2.24 times of that in RMG-I cells (P < 0.01) (Figure 3.
CD).
The mRNA levels of CD44 and a1,2-FT in RMG-I and
RMG-I-H cells
The 2-ΔΔCT value of mRNA level of CD44 in RMG-I-H
cells is 79% of that in RMG-I cells, which had no sig-
nificant difference (P > 0.05), whereas the mRNA level
of a1,2-FT in RMG-I-H cells was increased by 3.07
times of that in RMG-I cells detected by Real-time
PCR (P < 0.01). (Figure 4).
HA-mediated cell adhesion and spreading
The adhesion of RMG-I-H cells to HA was significantly
stronger than that of RMG-I cells (P < 0.01) (Table 2).
The adhesion of RMG-I-H and RMG-I cells to HA after
Lewis y antigen blocking was decreased respectively by
62.31% and 70.34% of irrelevant isotype-matched control
(P < 0.01), and no difference was observed between
these two cell lines (P > 0.05). Cell adhesion did not
change after treatment of normal mouse IgM, compared
with Lewis y antibody-untreated groups (P > 0.05).
Figure 1 The expression of CD44 in RMG-I and RMG-I-H cells detected by immunocytochemistry (×400). Panels 1 and 5 are negative
controls; panels 2 and 6 are Lewis y antibody-untreated cells; panels 3 and 7 are Lewis y antibody-treated cells; panels 4 and 8 are cells treated
by irrelevant isotype-matched control. The expression of CD44 was detected by SABC methods in RMG-I and RMG-I-H cells, and brown color
degree by DAB staining indicated the expression level of CD44. It can be seen from the figure that the expression of CD44 in the RMG-I-H cells
was stronger than that in RMG-I cells, which was decreased after Lewis y antibody blocking.
Table 1 The average optical density on
immunocytochemical staining with CD44 antibodies
Group RMG-I RMG-I-H
Negative control 0.02 ± 0.03 0.03 ± 0.01
Lewis y antibody-untreated 0.28 ± 0.02 0.49 ± 0.02*
Lewis y antibody-treated 0.11 ± 0.01** 0.11 ± 0.01**
Irrelevant isotype-matched control 0.26 ± 0.01 0.46 ± 0.01
* P < 0.01, vs. RMG-I cells; ** P < 0.01, vs. Irrelevant isotype-matched control.
Figure 2 Co-location of CD44 and Lewis y antigen on RMG-I-H
cells observed under confocal laser scanning microscope. Red
fluoscence on the upper left panel indicates CD44 expression; green
fluoscence on the upper right panel indicates Lewis y antigen
expression; blue fluoscence on the upper right panel indicates cell
nuclear location; the lower right panel is a merged image of the
other three panels. Lewis y antigen CD44 mainly expressed in the
cell membrane observed under the confocal laser scanning
microscope, and it were seen as yellow fluorescence after the two
overlap, suggesting that Lewis y antigen and CD44 co-localizated in
the cell membrane.
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On HA-coated plates, spreading RMG-I-H cells were
significantly more than spreading RMG-I cells (P < 0.01)
(Table 2). Cell spreading showed similar changes as cell
adhesion after Lewis y antigen blocking, suggesting that
Lewis y antigen was involved in the interaction of CD44
and HA.
Discussion
This article mainly found that Lewis y antigen, as a
structure in CD44 molecule, strengthens CD44-
mediated adhesion and spreading of ovarian cancer
cells. Inhibiting the expression of CD44 or blocking its
binding to receptors and downstream signal molecules
can inhibit the progression of ovarian cancer.
Glycoconjugates, an important component of cell
membrane, are involved in cell growth and differentia-
tion [15]. Fucose, the terminal residue of synthesized
sugar chains, is involved in constructing the sugar chain
structure of some important growth factor receptors
and plays an important role in tumorigenesis [16]. Stu-
dies showed that fucosylated antigens expressed in
tumor cells are involved in several cellular functions and
related to some malignant cell behaviors, including
adhesion, recognition, and signal transduction, and that
the increased fucosylated antigens benefit the invasion
and migration of tumor cells [17,18]. Ovarian cancer
mostly has changes of type II glycosylated antigens, such
as Lewis x, Lewis y and H antigens, which mainly
depend on the a1, 2-FT-catalyzed fucosylation of
galactose residues at the non-reducing terminal [19].
Our previous study showed that ovarian cancer cell line
RMG-I mainly expressed Lewis × antigen, and
confirmed that the enhanced adhesion of Lewis × anti-
gen-overexpressed cells to peritoneal mesothelia was
weakened after Lewis × antigen blocking in nude mouse
experiments, suggesting that Lewis × antigen is related
to the intraperitoneal dissemination of RMG-I cells [20].
We transfected wild type a1,2-FT gene into ovarian
cancer cell line RMG-I to establish the a1,2-FT-overex-
pressed cell line RMG-I-H, and found that the activity
of a1,2-FT in RMG-I-H cells was enhanced by 20 to
30 times [5]. We also found that only Lewis × and
Lewis y antigens in the type II lactose chain family were
expressed, 42.6% of Lewis × antigen in RMG-I-H cells
transformed into Lewis y antigen, and that the
Figure 3 The expression of CD44 and Lewis y antigen in RMG-I and RMG-I-H cells. Panel A shows the expression of Lewis y antigen in
RMG-I-H cells was higher than that in RMG-I; panel B shows the expression of CD44 in RMG-I-H cells was higher than that in RMG-I; panel C
shows that Lewis y antigen, which in RMG-I-H cells was higher than that in RMG-I, was expressed both in RMG-I and RMG-I-H cells after CD44
immunoprecipitation; panel D Quantitative data were expressed as the intensity ratio target genes to beta-actin. (P < 0.01).
Figure 4 The mRNA expression of CD44 and a1, 2-FT in RMG-I
and RMG-I-H cells were tested by quantitative Real-Time RT-
PCR. The mRNA level of a1, 2-FT was significantly increased, but the
mRNA level of CD44 was almost the same in RMG-1-hFUT cells and
RMG-1 cells. (**P < 0.01, * P > 0.05).
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concentration of Lewis y antigen in RMG-I-H cells was
increased by about 20 times of that in RMG-I cells[5].
After transfection of a1, 2-FT gene, while the expression
of Lewis y antigen in RMG-I-H cells was increased,
the malignant behaviors of cells were also enhanced, for
examples, the G1 phase of meiosis was shortened, the
colony formation rate on soft agar was increased,
the growth of subcutaneous and intraperitoneal xeno-
grafts in nude mice was accelerated, and the drug-
resistance was enhanced [6,21-23]. Lewis y antigen has
dual fucosylations–one more fucose than Lewis × anti-
gen. Lewis y monoclonal antibody or a-L-fucosidase can
significantly inhibit the proliferation and adhesion of
RMG-I-H cells [6,24], indicating that the effect of Lewis
y antigen on cell behaviors is stronger that that of Lewis
× antigen, which may due to the number of fucoses.
CD44, an important a1, 2-FT-containing protein on
cell surface, is involved in the adhesion and metastasis
of tumor cells, and plays an important role in tumor
progression [9]. Our present study showed that after
transfection of a1,2-FT gene, the expression of CD44 in
RMG-I-H cells was significantly increased together with
the increase of Lewis y antigen (P < 0.01). Confocal
laser scanning microscopy confirmed the co-location of
CD44 and Lewis y antigen, interpreted that Lewis y
antigen was a structure in CD44. In 2010, Lin et al. [25]
reported that both CD173(H2) and Lewis y(CD174)
could immunoprecipitate with CD44 in breast cancer
cells. Our results showed that the increase of Lewis y
antigen was more obvious, which increased by 2.24
times after a1, 2-FT gene transfection (P < 0.05). Lewis
y antibody can block the increase of CD44 expression.
We used gene chip to detect the differential expression
of genes in cells before and after transfection, and
found that 88 genes were differentially expressed after
transfection, which were involved in cell proliferation
and adhesion, signal transduction, protein phosphoryla-
tion, transcription, apoptosis, and so on[22]. However,
the change of CD44 after transfection was mainly at
protein level, with no obvious change at mRNA level
(P > 0.05). Yuan et al. [26] also believed that CD44 and
its several subtypes have post-transcriptional modifica-
tion, including the addition of glycosaminoglycan and
glycosylation.
The functions of a1, 2-FT in CD44 molecule are
unclear yet. Studies found that it can prevent decompo-
sition by proteolytic enzyme, enhance cell-cell adhesion,
and inhibit cell apoptosis [11]. Labarrière et al. [27] also
found that CD44v6 in mouse colon cancer cells contains
H antigen. Its fucose structure is involved in cell adhe-
sion, and the increase of its expression is related to the
decrease of the sensitivity to natural killer cells or the
decrease of the cytotoxicity of lymphocyte-activated
killer cells. Therefore, CD44v6 helps mouse colon can-
cer cells to escape from the recognition and killing by
the immune system, prone to invade lymph nodes and
form metastasis. Our study confirmed that the adhesion
and spreading of RMG-I-H cells to HA in extracellular
matrix were significantly enhanced (all P < 0.01). After
Lewis y antigen blocked, the expression of CD44 in cells
was decreased, cell adhesion and spreading were also
significantly decreased (all P < 0.01), suggesting that
Lewis y antigen plays an important role in mediating
the adhesion of CD44 to HA in extracellular matrix.
Yuan et al. [26] used a-L-fucosidase to treat breast can-
cer cells, and found that the expression of CD44 was
decreased; the adhesion of tumor cells to matrix was
decreased, resulting in a decrease of cell invasion. This
finding confirms our deduction.
The interaction of CD44 and HA activates RhoA
signals and Rho kinase, enhances serine/threonine phos-
phorylation on Gab-1 (Grb2-associated binder-1),
induces PI3K activation, triggers the PI3K/Akt pathway,
and is involved in the progression of breast cancer[28].
It is also confirmed that the binding of CD44 to HA
induces c-Src kinase activation, and is involved in the
metastasis of ovarian cancer cells by activating the c-Src
kinase pathway [29]. Our previous study showed that
the expression of Akt total protein in Lewis y antigen-
overexpressed ovarian cancer cells did not change, but it
phosphorylation was significantly enhanced; ZD1839
and Lewis y antibody decreased the level of phosphory-
lated Akt in Lewis y antigen-overexpressed cells, but
showed no effect in the ovarian cancer cells with low
Lewis y antigen expression. MTT assay showed that
PI3K-specific inhibitor LY294002 can significantly inhi-
bit the proliferation of Lewis y antigen-overexpressed
ovarian cancer cells [30].
Table 2 HA-mediated adhesion and spreading of RMG-I and RMG-I-H cells
Cell adhesion Cell spreading
Group RMG-I RMG-I-H RMG-I RMG-I-H
Lewis y antibody-untreated 1.41 ± 0.20 2.57 ± 0.58* 34 ± 5 57 ± 6*
Lewis y antibody-treated 0.53 ± 0.03** 0.76 ± 0.27** 16 ± 5** 14 ± 4**
Irrelevant isotype-matched control 1.36 ± 0.15 2.44 ± 0.67 35 ± 6 59 ± 8
* P < 0.01, vs. RMG-I cells; ** P < 0.01, vs. Irrelevant isotype-matched control.
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Ovarian cancer cells adhere to peritoneal mesothelia
via the formation of several compounds: CD44/HA,
b1-integrin/fibronectin, CA125/mesothelin, and so on
[31,32]. HA and fibronectin are components of extracel-
lular matrix. HA in extracellular matrix is a major
ligand of CD44. Many studies proved the importance of
CD44 and its receptors in the biological behaviors of
ovarian cancer [33]. Studies found that oncostatin M
and transforming growth factor 1 (TGF1) could mediate
the binding of HA to CD44 in tumor cells originated
from lung epithelia, leading to the glycosylation and
phosphatization of CD44 [34]. CD44 and HA mediate
the overexpression and activation of integrin as well as
the adhesion of tumor cells to epithelia, and enhance
the migration and metastasis of tumor cells [35]. Wie-
lenga et al. [36] reported that, in colorectal cancer,
heparin sulfate-modified CD44 showed increased ability
of binding to hepatocyte growth factor/scatter factor
(HGF/SF), thus presenting HGF/SF to c-Met and lead-
ing to c-Met phosphorylation, and triggering the c-Met
signal pathway to activate lymphocyte function-asso-
ciated antigen-1 (LFA-1), therefore, affecting the biolo-
gical activities of tumor cells, such as angiogenesis and
cell motivation. Zhang et al. [37] found that the binding
of HA to CD44 affected the adhesion of tumor cells via
some signal transduction pathways (such as the kinase
C pathway), and played an important role in tumor
metastasis. Kim et al. [38] used CD44 antibody to com-
petitively inhibit the binding of HA to CD44, and found
that the invasion of colorectal cancer cells to basement
membranes was decreased by 95%. The above findings
indicate that CD44 is involved in several signal trans-
duction pathways related to tumor cell metastasis, and
that inhibiting the expression of CD44 or blocking its
binding to receptors can inhibit the metastasis of tumor
cells. Our previous study showed that the expression of
EGFR, TGF-bR, a5b1, and a5b3 was also increased in
Lewis y antigen-overexpressed cells, and that Lewis y
antigen, as an important structure in EGFR, TGF-bR,
a5b1, and a5b3 (unpublished data), affected the biologi-
cal behaviors of cells by activating the Raf/MEK/MAPK,
PI3K/Akt, TGF-b/Smads, and FAK signal pathways
[39,40].
In summary, Lewis y antigen is overexpressed on
ovarian cancer cells, and is homogeneous in primary
and metastatic lesions; hence, it has become a target
antigen of immune therapy.
Conclusions
We have transfected the alfa1, 2-fucosyltransferase gene
into cultured cells from an ovarian carcinoma and
showed that the transfected cells have elevated expres-
sion of CD44 with Lewis y resulting in their increased
ability to adhere and to spread via the CD44-hyaluronic
acid interaction. The paper demonstrates a novel role of
Lewis y in regulating the CD44- hyaluronic interaction.
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